SMC Update - February 2025
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Netarsudil / latanoprost (Roclanda®) has been accepted for restricted use in the treatment of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. The restriction limits use to patients for whom treatment with a prostaglandin analogue alone provides insufficient IOP reduction, only if:
- the patient has then tried a fixed-dose combination treatment and it has not sufficiently reduced IOP, or
- a fixed-dose combination treatment containing beta-blockers is unsuitable
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « CKS Updates - January 2025 | FSRH Statement On GLP-1 Agonists » |
Leave a Comment